Atavistik Bio’s high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable Atavistik to discover first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. The unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems—including clinical metabolomic data sets—to apply to genetically-validated targets in metabolic diseases and cancer.